Direkt zum Inhalt
Merck

Y0001388

Candesartancilexetil

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

2-Ethoxy-1-[[2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl]methyl]-1H-benzimidazol-7-carbonsäure-1-[[(cyclohexyloxy)carbonyl]oxy]ethylester, TCV 116, TCY 116

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C33H34N6O6
CAS-Nummer:
Molekulargewicht:
610.66
MDL-Nummer:
UNSPSC-Code:
41116107
PubChem Substanz-ID:
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

candesartan

Hersteller/Markenname

EDQM

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

SMILES String

CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc4ccc(cc4)-c5ccccc5-c6nnn[nH]6

InChI

1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38)

InChIKey

GHOSNRCGJFBJIB-UHFFFAOYSA-N

Angaben zum Gen

human ... AGTR1(185)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Candesartan cilexetil EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem./physiol. Wirkung

Candesartancilexetil ist die Prodrug-Form des potenten Angiotensin II-Rezeptorantagonisten Candesartan. Das Prodrug wird durch Esterasen im Darm gespaltet, um das aktive Molekül freizusetzen.

Verpackung

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

Piktogramme

Health hazard

Signalwort

Danger

H-Sätze

Gefahreneinstufungen

Repr. 1B - STOT RE 2 Oral

Zielorgane

Kidney,Blood

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Leider sind derzeit keine COAs für dieses Produkt online verfügbar.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Greg L Plosker et al.
PharmacoEconomics, 24(12), 1249-1272 (2006-11-30)
The addition of candesartan cilexetil (Atacand, Amias, Blopress, Kenzen, Ratacand) to standard therapy for chronic heart failure (CHF) provided important clinical benefits at little or no additional cost in France, Germany and the UK, according to a detailed economic analysis
Gerd Bönner et al.
Current medical research and opinion, 21(6), 935-940 (2005-06-23)
Candesartan cilexetil is a highly potent and long-acting angiotensin II type I (AT1) receptor antagonist. This short review summarises results of clinical studies focusing on the duration of action of candesartan cilexetil. Results of previous clinical studies indicate that candesartan
G Mancia et al.
Journal of human hypertension, 14 Suppl 2, S3-10 (2000-11-22)
The prevention and treatment of hypertension both from the viewpoint of individual patient care and in terms of population health presents a considerable challenge to the medical profession. To assist in meeting this challenge, various bodies have produced guidelines for
Peter A Meredith
Current medical research and opinion, 23(7), 1693-1705 (2007-06-26)
Therapeutic interventions that block the renin-angiotensin-aldosterone system (RAAS) have an important role in slowing the progression of cardiovascular risk actors to established cardiovascular diseases. In recent years, angiotensin receptor blockers (ARBs) have emerged as effective and well-tolerated alternatives to an
Naoki Ichikawa et al.
Neurological research, 37(2), 147-152 (2014-08-05)
The purpose of this study was to examine whether oral administration of an angiotensin II type 1 receptor blocker (ARB) inhibited in-stent neointimal hyperplasia in carotid arteries of hypercholesterolemic rabbits. Eleven male New Zealand white rabbits were subjected to endothelial

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.